Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)

2. ledna 2020 aktualizováno: Xuemei Huang, MD, PhD, Milton S. Hershey Medical Center

Multimodal MRI Markers of Nigrostriatal Pathology in Parkinson's Disease

This study is designed to determine if magnetic resonance imaging (MRI) measures can be used to diagnose and monitor the progression of Parkinson's disease (PD) while distinguishing between PD and parkinsonisms [conditions that are PD look-a-like diseases such as progressive supranuclear palsy (PSP) or multiple system atrophy (MSA)] when combined with changes in certain proteins in body fluids that are related to iron (Fe).

Přehled studie

Detailní popis

The lack of in vivo biomarker(s) reflecting Parkinson's disease (PD)-related cell loss and associated pathoetiological/physiological processes in nigrostriatal structures has hindered discovery research and limited the ability to evaluate disease-modifying therapies. Recent research has generated excitement for using DTI and R2* MRI measures as biomarker(s) for PD-related pathology in nigrostriatal pathways, but they fall short by the lack of understanding of their clinical implications and biological/pathological underpinnings. Working closely with the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarkers Program (PDBP), the proposed work will investigate multimodal MRI techniques in combination with fluid-based iron (Fe) protein profiles to serve as in vivo markers for PD-related nigrostriatal pathology that can be used as biomarkers for diagnosing PD, following its progression, and gaining mechanistic understanding of PD pathoetiology and pathophysiology.

Typ studie

Pozorovací

Zápis (Aktuální)

290

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Pennsylvania
      • Hershey, Pennsylvania, Spojené státy, 17033
        • Penn State Milton S. Hershey Medical Center and College of Medicine

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

21 let až 90 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

Clinical patients and community volunteers

Popis

Inclusion Criteria:

PD Subjects:

  1. Able and willing to sign the consent form at time of initial enrollment or if the subject is decisionally impaired and has a legal representative that is able and willing to sign a consent form at the time of the enrollment. If the subject becomes decisionally impaired during the course of the study, their legal representative may sign an addendum to consent for continued participation.
  2. MMSE score of 15 or greater unless a legal representative is present.
  3. Idiopathic PD according to published criteria.
  4. History of adequate response to dopaminergic therapy.
  5. History of asymmetrical symptom onset

MSA Subjects:

  1. Older than 30 yrs.
  2. Able and willing to sign the consent form at time of initial enrollment or if the subject is decisionally impaired and has a legal representative that is able and willing to sign a consent form at the time of the enrollment. If the subject becomes decisionally impaired during the course of the study, their legal representative may sign an addendum to consent for continued participation.
  3. MMSE score of 15 or greater unless a legal representative is present.
  4. MSA according to published criteria.
  5. History of autonomic & urinary dysfunction and/or severe cerebellar ataxia.

PSP Subjects:

  1. Older than 40 yrs.
  2. Able and willing to sign the consent form at time of initial enrollment or if the subject is decisionally impaired and has a legal representative that is able and willing to sign a consent form at the time of the enrollment. If the subject becomes decisionally impaired during the course of the study, their legal representative may sign an addendum to consent for continued participation.
  3. PSP according to published criteria.
  4. Vertical gaze palsy and/or slow vertical gaze/postural instability during first year of diagnosis.
  5. MMSE score of 15 or greater unless a legal representative is present

Controls:

  1. Older than 21 yrs.
  2. Able and willing to sign the consent form.
  3. MMSE greater than 24.

Exclusion Criteria:

PD Subjects:

  1. Unable or does not have a legal representative/unwilling to provide consent.
  2. Any condition that precludes a routine MRI (e.g., claustrophobia, pacemaker, severe scoliosis, etc.).
  3. History of cerebrovascular diseases or other neurological disorders.
  4. Major medical problems such as renal or liver failure.
  5. Unstable, non-PD-related medical conditions.
  6. MMSE score less than 15 unless a legal representative is present
  7. Use of anticoagulant medications.
  8. Signs of dementia.

MSA Subjects:

  1. Unable or does not have a legal representative /unwilling to provide consent.
  2. Any condition that precludes a routine MRI (e.g., claustrophobia, pacemaker, severe scoliosis, etc.).
  3. History of cerebrovascular diseases or other neurological disorders.
  4. Major medical problems such as renal or liver failure.
  5. Unstable, non-MSA-related medical conditions.
  6. MMSE score less than 15 unless a legal representative is present
  7. Use of anticoagulant medications.
  8. Signs of dementia.

PSP Subjects:

  1. Unable or does not have a legal representative /unwilling to provide consent.
  2. Any condition that precludes a routine MRI (e.g., claustrophobia, pacemaker, severe scoliosis, etc.).
  3. History of cerebrovascular diseases or other neurological disorders.
  4. Major medical problems such as renal or liver failure.
  5. Unstable, non-PSP-related medical conditions.
  6. MMSE score less than 15 unless a legal representative is present
  7. Use of anticoagulant medications.
  8. Signs of dementia.

Controls:

  1. Unable/unwilling to provide consent.
  2. Evidence of severe memory impairment or signs of dementia (MMSE < 24).
  3. Any condition that precludes a routine MRI (e.g., claustrophobia, pacemaker, severe scoliosis, etc.).
  4. History of cerebrovascular diseases or other neurological disorders.
  5. Major medical problems such as renal or liver failure.
  6. Unstable medical conditions.
  7. Use of anticoagulant medications.
  8. Signs of dementia.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

Kohorty a intervence

Skupina / kohorta
Parkinson's Disease (PD)
Patients with a clinical diagnosis of PD (in various stages)
Progressive supranuclear palsy (PSP)
Patients with a clinical diagnosis of PSP (in various stages)
Multiple system atrophy (MSA)
Patients with a clinical diagnosis of MSA (in various stages)
Controls
Age and gender-matched adults free from neurological disease

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Differential roles of fractional anisotropy (FA) and R2* in PD detection and progression
Časové okno: Change in roles of FA and R2* assessed between baseline and 18 months. Change assessed between baseline and 36 months. Change assessed between 18 and 36 months.
Substantia Nigra (SN) FA and R2* values in PD subjects will be compared with control subjects and correlated with clinical and behavioral measures.
Change in roles of FA and R2* assessed between baseline and 18 months. Change assessed between baseline and 36 months. Change assessed between 18 and 36 months.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Nigrostriatal diffusion tensor imaging (DTI) and R2* differentiate PD from parkinsonian syndromes
Časové okno: Assessed at baseline visit.
DTI and R2* measures in both SN and striatal structures in PD, PSP, MSA and control subjects will be compared to assess sensitivity and specificity of individual and combined MRI measures in diagnosing PD.
Assessed at baseline visit.
Iron(Fe)-related proteins in body fluids as biomarkers of PD
Časové okno: Change assessed between baseline and 18 months. Change assessed between baseline and 36 months. Change assessed between 18 and 36 months.
The protein profile in blood, urine, and cerebral spinal fluid (CSF), and their relationships to clinical and MRI measure will be interrogated with the focus being on Fe-related proteins such as hepcidin, ferritin, and transferrin.
Change assessed between baseline and 18 months. Change assessed between baseline and 36 months. Change assessed between 18 and 36 months.
MRI and postmortem pathological correlation
Časové okno: From baseline until date of death from any cause within 5 years for patient participants who succumb to their disease
Postmortem brain analysis on patients who succumb to their disease during the study will be performed in order to inform the relationship of the biomarkers to clinical diagnosis (PD, PSP, MSA) and clinical milestones as well as to inform the pathological underpinnings of the R2* and DTI measures. In addition to standard postmortem diagnostic tests (alpha-synuclein, beta-amyloid, tau, and ubiquitin), total Fe staining, ferritin, hepcidin, tyrosine hydroxylase positive neurons, myelin and glial derived growth factors (glial cell markers) will be assessed in nigrostriatal structures in order to correlate these levels with MRI measures.
From baseline until date of death from any cause within 5 years for patient participants who succumb to their disease

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia

1. prosince 2012

Primární dokončení (Aktuální)

1. prosince 2019

Dokončení studie (Aktuální)

31. prosince 2019

Termíny zápisu do studia

První předloženo

17. ledna 2013

První předloženo, které splnilo kritéria kontroly kvality

25. června 2013

První zveřejněno (Odhad)

27. června 2013

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

3. ledna 2020

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

2. ledna 2020

Naposledy ověřeno

1. ledna 2020

Více informací

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

3
Předplatit